EDITAS MEDICINE, INC. (EDIT) Debt / Equity
- 2026-06-30: Debt/Equity Ratio 0.53.
- 2026-03-31: Debt/Equity Ratio 12.4.
- 2025-12-31: Debt/Equity Ratio 2.15.
- 2025-09-30: Debt/Equity Ratio 4.39.
Complete source-backed debt/equity ratio history.
- Available history
- 2023-12-31 to 2026-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2026-06-30 | 0.53 |
| 2026-03-31 | 12.4 |
| 2025-12-31 | 2.15 |
| 2025-09-30 | 4.39 |
| 2025-06-30 | 2.95 |
| 2025-03-31 | 0.87 |
| 2024-12-31 | 0.43 |
| 2023-12-31 | 0 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 2.15 |
| 2024-12-31 | 0.43 |
| 2023-12-31 | 0 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |